Literature DB >> 7216489

Immunotherapy of experimental cancer with a mixture of synthetic muramyl dipeptide and trehalose dimycolate.

E Yarkoni, E Lederer, H J Rapp.   

Abstract

The antitumor activity of a mixture of synthetic N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP) and trehalose-6,6'-dimycolate (TDM) (MDP+TDM) in emulsified form was studied in guinea pigs, each with a syngeneic dermal tumor and microscopically detectable metastases in regional lymph nodes. A single intralesional administration of an ultrasonically prepared emulsion containing MDP+TDM in squalane or in mineral oil caused tumor regression and elimination of lymph node metastases. Similar emulsions of MDP+TDM made with squalene or hexadecane were immunotherapeutically inactive.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7216489      PMCID: PMC350617          DOI: 10.1128/iai.32.1.273-276.1981

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  7 in total

1.  Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives.

Authors:  F Ellouz; A Adam; R Ciorbaru; E Lederer
Journal:  Biochem Biophys Res Commun       Date:  1974-08-19       Impact factor: 3.575

Review 2.  A guinea pig model for tumor immunology. A summary.

Authors:  H J Rapp
Journal:  Isr J Med Sci       Date:  1973-03

3.  Enhancement of endotoxic shock by N-acetylmuramyl-L-alanyl-(L-seryl)-D-isoglutamine (muramyl dipeptide).

Authors:  E E Ribi; J L Cantrell; K B Von Eschen; S M Schwartzman
Journal:  Cancer Res       Date:  1979-11       Impact factor: 12.701

4.  Tumor regression after intralesional injection of emulsified trehalose-6,6'-dimycolate (cord factor): efficacy increases with oil concentration.

Authors:  E Yarkoni; M S Meltzer; H J Rapp
Journal:  Int J Cancer       Date:  1977-06-15       Impact factor: 7.396

5.  Immunoadjuvant activities of synthetic N-acetyl-muramyl-peptides or -amino acids.

Authors:  S Kotani; Y Watanabe; F Kinoshita; T Shimono; I Morisaki
Journal:  Biken J       Date:  1975-06

6.  Regression of tumors in guinea pigs after treatment with synthetic muramyl dipeptides and trehalose dimycolate.

Authors:  C A McLaughlin; S M Schwartzman; B L Horner; G H Jones; J G Moffatt; J J Nestor; D Tegg
Journal:  Science       Date:  1980-04-25       Impact factor: 47.728

7.  Influence of type of oil and surfactant concentration on the efficacy of emulsified Mycobacterium bovis BCG cell walls to induce tumor regression in guinea pigs.

Authors:  E Yarkoni; H J Rapp
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

  7 in total
  13 in total

1.  MSU Crystals Enhance TDB-Mediated Inflammatory Macrophage IL-1β Secretion.

Authors:  Kanu Wahi; Kristel Kodar; Melanie J McConnell; Jacquie L Harper; Mattie S M Timmer; Bridget L Stocker
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

Review 2.  Muramyl peptides. Chemical structure, biological activity and mechanism of action.

Authors:  A Adam; J F Petit; P Lefrancier; E Lederer
Journal:  Mol Cell Biochem       Date:  1981-12-04       Impact factor: 3.396

3.  Antitumor and antimetastatic activity of the immunoadjuvant peptidoglycan monomer PGM in mice bearing MCa mammary carcinoma.

Authors:  G Sava; J Tomasic; I Hrsak
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

4.  Enhancement of resistance to Escherichia coli infection in mice by dihydroheptaprenol, a synthetic polyprenol derivative.

Authors:  S Araki; K Kagaya; K Kitoh; M Kimura; Y Fukazawa
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

5.  Antimetastatic effect of immunomodulators from Nocardia opaca in mice and rats activation of peritoneal macrophages by these fractions.

Authors:  R Barot-Ciorbaru; I Cornil; T Grand-Perret; M F Poupon
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

6.  Persistent enhancement of cell-mediated and antibody immune responses after administration of muramyl dipeptide derivatives with antigen in metabolizable oil.

Authors:  C Carelli; F Audibert; L Chedid
Journal:  Infect Immun       Date:  1981-07       Impact factor: 3.441

7.  Modulation of natural killer cytotoxicity by muramyl dipeptide and trehalose dimycolate incorporated in squalane droplets.

Authors:  K N Masihi; W Lange; B Rohde-Schulz
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

8.  Inhibition of tumor growth in mice treated with synthetic muramyl dipeptide.

Authors:  J Bubeník; J Jezek; M Zaoral; J Hofmann; Y V Gruntenko; J G Osipov; A G Zolotareva; T E Vakhrusheva; V G Budker
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

9.  A specific vaccine effective against stage I and stage II malignant disease in guinea pigs. Effect of variations in preparations and storage.

Authors:  E Yarkoni; J T Hunter; S Sukumar
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

10.  Parallel antitumor, granuloma-forming and tumor-necrosis-factor-priming activities of mycoloyl glycolipids from Nocardia rubra that differ in carbohydrate moiety: structure-activity relationships.

Authors:  Y Natsuhara; S Oka; K Kaneda; Y Kato; I Yano
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.